非小细胞肺癌的新辅助治疗
Neoadjuvant therapy in non-small cell lung cancer.
作者信息
Grant Christopher, Hagopian Garo, Nagasaka Misako
机构信息
Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA.
Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA; Division of Hematology and Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA; Division of Neurology, Department of Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
出版信息
Crit Rev Oncol Hematol. 2023 Oct;190:104080. doi: 10.1016/j.critrevonc.2023.104080. Epub 2023 Aug 1.
Non-small cell lung cancer (NSCLC) stages I-III were previously predominantly treated with surgery and chemotherapy. With the advent of Checkmate-816, neoadjuvant nivolumab and chemotherapy was FDA approved for the treatment of resectable NSCLC. There are several ongoing trials evaluating other neoadjuvant combinations of chemotherapy and immunotherapy as well as targeted therapies towards driver mutations. Here, we review previous clinical trials and discuss current ongoing trials' potential benefits and challenges.
非小细胞肺癌（NSCLC）的I-III期患者以前主要接受手术和化疗。随着Checkmate-816的出现，新辅助纳武单抗联合化疗获得美国食品药品监督管理局（FDA）批准用于可切除NSCLC的治疗。目前有几项正在进行的试验，评估化疗与免疫疗法的其他新辅助联合方案以及针对驱动基因突变的靶向疗法。在此，我们回顾以往的临床试验，并讨论当前正在进行的试验的潜在益处和挑战。
Zotero 插件